Page last updated: 2024-11-05

thalidomide and Anemia, Sickle Cell

thalidomide has been researched along with Anemia, Sickle Cell in 12 studies

Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.

Anemia, Sickle Cell: A disease characterized by chronic hemolytic anemia, episodic painful crises, and pathologic involvement of many organs. It is the clinical expression of homozygosity for hemoglobin S.

Research Excerpts

ExcerptRelevanceReference
"Thalidomide alone was also more effective in decreasing H3K27 methylation."2.78Evaluation of H3 histone methylation and colony formation in erythroid progenitors treated with thalidomide and sodium butyrate. ( Abroun, S; Ahmadvand, M; Chegeni, R; Fard, AD; Hajifathali, A; Kaviani, S; Mohammadi, MM; Noruzinia, M; Saki, N; Soleimani, M; Zonoubi, Z, 2013)
"Current therapeutic strategies for sickle cell anemia are aimed at reactivating fetal hemoglobin."1.43Pomalidomide reverses γ-globin silencing through the transcriptional reprogramming of adult hematopoietic progenitors. ( Al-Abed, Y; Allen, SL; An, X; Appiah-Kubi, AO; Blanc, L; Chan, KW; Didier, S; Dulmovits, BM; Gallagher, PG; Gould, M; Hale, J; He, M; Husain-Krautter, S; Lipton, JM; Liu, JM; Marambaud, P; Mohandas, N; Papoin, J; Singh, SA; Taylor, N; Vlachos, A, 2016)
"Pomalidomide is a potent structural analog of thalidomide and member of a new class of immunomodulatory drugs."1.37Pomalidomide augments fetal hemoglobin production without the myelosuppressive effects of hydroxyurea in transgenic sickle cell mice. ( Corral, LG; Kutlar, A; Kutlar, F; Meiler, SE; Moutouh-de Parseval, LA; Swerdlow, PS; Wade, M; Xue, Y; Yerigenahally, SD, 2011)
"Sickle-cell disease (SCD) and beta thalassemia constitute worldwide public health problems."1.35Pomalidomide and lenalidomide regulate erythropoiesis and fetal hemoglobin production in human CD34+ cells. ( Brady, H; Chan, K; Corral, LG; Ferguson, GD; Glezer, E; Jensen-Pergakes, K; Morris, CL; Moutouh-de Parseval, LA; Muller, G; Verhelle, D, 2008)

Research

Studies (12)

TimeframeStudies, this research(%)All Research%
pre-19901 (8.33)18.7374
1990's0 (0.00)18.2507
2000's2 (16.67)29.6817
2010's7 (58.33)24.3611
2020's2 (16.67)2.80

Authors

AuthorsStudies
Melo, TRF1
Kumkhaek, C1
Fernandes, GFDS2
Lopes Pires, ME1
Chelucci, RC1
Barbieri, KP1
Coelho, F1
Capote, TSO1
Lanaro, C4
Carlos, IZ1
Marcondes, S1
Chegaev, K1
Guglielmo, S1
Fruttero, R1
Chung, MC2
Costa, FF4
Rodgers, GP1
Dos Santos, JL4
Khandros, E1
Huang, P1
Peslak, SA1
Sharma, M1
Abdulmalik, O1
Giardine, BM1
Zhang, Z1
Keller, CA1
Hardison, RC1
Blobel, GA1
de Melo, TRF1
Dulmovits, BM2
de Souza, CM1
He, M2
Al Abed, Y1
Blanc, L2
Franco-Penteado, CF2
Silva, FH1
Fertrin, KY1
Wade, M3
Yerigenahally, S2
de Melo, TR1
Chin, CM1
Kutlar, A3
Meiler, SE3
Fard, AD2
Kaviani, S2
Noruzinia, M2
Soleimani, M1
Abroun, S1
Chegeni, R1
Hajifathali, A1
Zonoubi, Z1
Ahmadvand, M1
Mohammadi, MM1
Saki, N2
Mortaz, E1
Appiah-Kubi, AO1
Papoin, J1
Hale, J1
Al-Abed, Y1
Didier, S1
Gould, M1
Husain-Krautter, S1
Singh, SA1
Chan, KW1
Vlachos, A1
Allen, SL1
Taylor, N1
Marambaud, P1
An, X1
Gallagher, PG1
Mohandas, N1
Lipton, JM1
Liu, JM1
Kutlar, F1
Yerigenahally, SD1
Xue, Y1
Moutouh-de Parseval, LA2
Corral, LG3
Swerdlow, PS1
Lima, LM1
Gambero, S1
Alexandre-Moreira, MS1
Chung, M1
Ferguson, GD2
Jensen-Pergakes, K2
Wilkey, C1
Jhaveri, U1
Richard, N1
Verhelle, D2
De Parseval, LM1
Xie, W1
Morris, CL2
Brady, H2
Chan, K2
Glezer, E1
Muller, G1
Achs, R1
Harper, RG1

Reviews

2 reviews available for thalidomide and Anemia, Sickle Cell

ArticleYear
Induction of fetal hemoglobin as a novel therapeutic strategy for β-hemoglobinopathy.
    Laboratory hematology : official publication of the International Society for Laboratory Hematology, 2014, Mar-01, Volume: 20, Issue:1

    Topics: Anemia, Sickle Cell; Angiogenesis Inhibitors; Animals; beta-Thalassemia; Butyric Acid; Drug Synergis

2014
Dermatoglyphics.
    American journal of obstetrics and gynecology, 1968, Aug-01, Volume: 101, Issue:7

    Topics: Abnormalities, Drug-Induced; Anemia, Sickle Cell; Anencephaly; Cerebral Palsy; Chromosome Aberration

1968

Trials

1 trial available for thalidomide and Anemia, Sickle Cell

ArticleYear
Evaluation of H3 histone methylation and colony formation in erythroid progenitors treated with thalidomide and sodium butyrate.
    Laboratory hematology : official publication of the International Society for Laboratory Hematology, 2013, Volume: 19, Issue:1

    Topics: AC133 Antigen; Anemia, Sickle Cell; Antigens, CD; beta-Thalassemia; Butyrates; Cells, Cultured; Eryt

2013

Other Studies

9 other studies available for thalidomide and Anemia, Sickle Cell

ArticleYear
Discovery of phenylsulfonylfuroxan derivatives as gamma globin inducers by histone acetylation.
    European journal of medicinal chemistry, 2018, Jun-25, Volume: 154

    Topics: Acetic Acid; Acetylation; Anemia, Sickle Cell; Dose-Response Relationship, Drug; Drug Discovery; gam

2018
Understanding heterogeneity of fetal hemoglobin induction through comparative analysis of F and A erythroblasts.
    Blood, 2020, 05-28, Volume: 135, Issue:22

    Topics: Adult; Anemia, Sickle Cell; Cell Line; Cell Separation; Cells, Cultured; Erythroblasts; Erythroid Ce

2020
Synthesis and pharmacological evaluation of pomalidomide derivatives useful for sickle cell disease treatment.
    Bioorganic chemistry, 2021, Volume: 114

    Topics: Anemia, Sickle Cell; Dose-Response Relationship, Drug; Humans; Molecular Structure; Structure-Activi

2021
A thalidomide-hydroxyurea hybrid increases HbF production in sickle cell mice and reduces the release of proinflammatory cytokines in cultured monocytes.
    Experimental hematology, 2018, Volume: 58

    Topics: Anemia, Sickle Cell; Animals; Cytokines; Disease Models, Animal; Fetal Hemoglobin; Hydroxyurea; Infl

2018
Pomalidomide reverses γ-globin silencing through the transcriptional reprogramming of adult hematopoietic progenitors.
    Blood, 2016, Mar-17, Volume: 127, Issue:11

    Topics: Adult; Anemia, Sickle Cell; beta-Globins; Carrier Proteins; Erythroid Precursor Cells; Erythropoiesi

2016
Pomalidomide augments fetal hemoglobin production without the myelosuppressive effects of hydroxyurea in transgenic sickle cell mice.
    Blood, 2011, Jul-28, Volume: 118, Issue:4

    Topics: Anemia, Sickle Cell; Animals; Antisickling Agents; Bone Marrow; Disease Models, Animal; Erythropoies

2011
Design, synthesis, and pharmacological evaluation of novel hybrid compounds to treat sickle cell disease symptoms.
    Journal of medicinal chemistry, 2011, Aug-25, Volume: 54, Issue:16

    Topics: Acetic Acid; Analgesics; Anemia, Sickle Cell; Animals; Anti-Inflammatory Agents; Antisickling Agents

2011
Immunomodulatory drug CC-4047 is a cell-type and stimulus-selective transcriptional inhibitor of cyclooxygenase 2.
    Journal of clinical immunology, 2007, Volume: 27, Issue:2

    Topics: Anemia, Sickle Cell; Anti-Inflammatory Agents, Non-Steroidal; Blotting, Western; Cyclooxygenase 2; C

2007
Pomalidomide and lenalidomide regulate erythropoiesis and fetal hemoglobin production in human CD34+ cells.
    The Journal of clinical investigation, 2008, Volume: 118, Issue:1

    Topics: Anemia, Sickle Cell; Antigens, CD34; Antineoplastic Agents; Antisickling Agents; beta-Thalassemia; B

2008